What Critical Medical Contraindications And Pre-Treatment Screening Steps Should Clinical Practitioners Consider Before Operating Q-Switched Ruby Laser Systems For Pigmented Lesion Removal?

Before using a Q-switched ruby laser, practitioners must first establish that the lesion is benign and identify factors that could cause permanent pigmentary or scarring complications. The two most critical exclusions are systemic gold exposure and possible malignancy. A complete medication, skin, sun-exposure, scarring, and ocular-safety assessment should precede treatment, with biopsy performed whenever the diagnosis is uncertain.

Do not laser an undiagnosed or suspicious pigmented lesion. Exclude melanoma and atypical melanocytic proliferation through appropriate clinical assessment and biopsy, and avoid treatment in patients with current systemic gold therapy because of the risk of irreversible chrysiasis.

Establish That the Lesion Is Appropriate for Laser Treatment

Biopsy suspicious or diagnostically uncertain lesions

Any lesion showing asymmetry, border irregularity, color variation, recent change, ulceration, bleeding, or atypical melanocytic features should not be treated cosmetically.

A diagnostic biopsy is required when malignancy cannot be confidently excluded. Laser destruction can eliminate clinically important features and delay melanoma diagnosis.

Use histology to guide treatment planning

When biopsy is performed, histology may help determine whether the target pigment is primarily epidermal or dermal.

This information supports selection of wavelength, fluence, and treatment expectations. It does not, however, replace the need for a complete clinical examination.

Do not treat lesions that require ongoing surveillance

Avoid laser treatment when removing the pigment would make future monitoring difficult, particularly for lesions with atypical features or uncertain biological behavior.

A history of melanoma should prompt careful dermatologic assessment. A family history alone is not universally an absolute contraindication, but it lowers the threshold for specialist evaluation and biopsy.

Screen for the Most Important Medication Risks

Systemic gold therapy is a critical contraindication

Patients currently taking, or with a relevant history of taking, systemic gold-containing medications or gold salts should not undergo Q-switched ruby laser treatment without specialist assessment.

Laser exposure can alter cutaneous gold deposits and produce chrysiasis—a potentially permanent blue-gray or mottled blue-gray discoloration, especially in sun-exposed skin. The medication history should include drugs prescribed for rheumatologic or other inflammatory conditions.

Review isotretinoin and other systemic retinoids

Ask specifically about current or recent oral isotretinoin and other systemic retinoid use.

The historical concern is impaired wound healing and hypertrophic or keloidal scarring. The appropriate delay is not uniform across all procedures or guidelines, so clinicians should follow current dermatology guidance, the device labeling, and the prescribing clinician’s assessment rather than applying an automatic interval without context.

Identify drugs that can create or alter pigmentation

Document medications associated with drug-induced pigmentation, including agents such as minocycline, amiodarone, tetracyclines, antimalarials, phenytoin, imipramine, chlorpromazine, and ketoconazole.

These drugs may change the lesion’s appearance, complicate diagnosis, or alter the expected response to laser treatment. The underlying cause of pigmentation should be clarified before treatment.

Review photosensitizing medications and conditions

Ask about medications and medical conditions that increase photosensitivity. Treatment should be deferred or medically reviewed when active photosensitivity, lupus, or another light-sensitive disorder is present.

The screening process should also distinguish true contraindications from precautions that require altered parameters or closer monitoring.

Assess Sun Exposure and Epidermal Melanin

Postpone treatment after tanning or sunburn

Recent natural tanning, tanning-bed exposure, or sunburn increases epidermal melanin and therefore increases competition for ruby-laser energy.

Treatment should be postponed until the tan or inflammation has resolved. A conservative sun-avoidance interval—often several weeks according to clinical protocol—should be used, with strict broad-spectrum sunscreen afterward.

Recognize the risk in darker skin phototypes

The 694 nm ruby wavelength is strongly absorbed by melanin, including epidermal melanin. This increases the risk of burns, post-inflammatory hyperpigmentation, hypopigmentation, and textural change in darker skin phototypes.

For Fitzpatrick skin types IV–VI, clinicians should use particular caution, consider whether another wavelength is safer, and avoid treating recently tanned skin.

Consider pre-treatment pigment control carefully

Some protocols use topical agents such as hydroquinone or kojic acid for two to three weeks before treatment, together with broad-spectrum SPF 50+ protection.

These measures are not substitutes for diagnosis or sun avoidance. They should be prescribed and monitored appropriately, particularly when hydroquinone is used.

Evaluate Healing, Scarring, and Local Skin Conditions

Ask about abnormal scarring and poor wound healing

Document any history of keloids, hypertrophic scars, delayed healing, or severe post-inflammatory pigment alteration.

Patients with these histories may face increased risk and may require specialist review, conservative test spots, or avoidance of treatment.

Exclude active local disease

Do not treat over active infection, significant dermatitis, open wounds, or inflamed skin.

Use additional caution with disorders that may koebnerize or undergo pigmentary change, including vitiligo and psoriasis. Active radiation therapy, significant bleeding disorders, or other conditions that impair healing also require medical review before treatment.

Review herpes simplex history

For patients with a history of recurrent HSV at or near the treatment site, consider antiviral prophylaxis according to local clinical protocol.

The regimen should be selected by the treating clinician and started sufficiently before treatment when indicated.

Account for hair and adjacent pigmented structures

Ruby laser energy can temporarily or permanently whiten hair within the treatment field, including hair in a beard area or within a hairy nevus.

Patients should be informed in advance. Do not assume that hair depilation precautions used for laser hair removal apply identically to pigmented-lesion treatment; the relevant issue is avoiding unintended treatment of structures not included in the treatment plan.

Complete Safety Screening Before Activating the Laser

Protect the eyes

Q-switched lasers can create intense optical and acoustic effects, and accidental ocular exposure can cause serious retinal injury.

All patients and personnel in the treatment room must use wavelength-appropriate, certified protective eyewear. Eyewear should remain in place until the system is fully placed in standby or otherwise rendered safe according to the manufacturer’s instructions.

Perform a test spot

A test treatment helps assess tissue response and refine fluence before treating a larger area.

The response should be reviewed after an appropriate interval, particularly in darker skin types or when the diagnosis, skin condition, or treatment response is uncertain.

Confirm device and treatment parameters

Verify the wavelength, spot size, beam profile, pulse settings, and fluence against the device’s instructions and the lesion’s characteristics.

A flat-top beam and appropriately large spot size may improve energy uniformity, but device-specific settings must be determined by a trained operator rather than copied from a generic protocol.

Document informed consent

Consent should cover expected outcomes, the possibility of incomplete clearance, multiple sessions, recurrence, and pigmentary complications.

It should also specifically address hypopigmentation, hyperpigmentation, scarring, textural change, lesion recurrence, and temporary hair whitening.

Understanding the Trade-offs

“Benign” does not mean “safe to laser immediately”

A lesion may appear benign while still requiring biopsy because laser treatment removes the visual and histologic evidence needed for diagnosis.

When there is meaningful diagnostic uncertainty, the safer choice is dermatologic evaluation and tissue diagnosis—not a test spot.

Shorter wavelengths improve pigment absorption but increase epidermal risk

The ruby wavelength is effective because it is strongly absorbed by melanin. The same property increases epidermal injury risk when the skin contains more melanin from baseline pigmentation or recent tanning.

This is why patient selection, sun control, conservative testing, and parameter selection are central to safety.

A test spot cannot eliminate all risk

A favorable test response reduces uncertainty but does not guarantee that a full treatment will be complication-free.

Avoid pulse stacking and excessive spot overlap, and use careful spacing and conservative escalation to limit thermal injury and dyschromia.

Supplementary screening items should be interpreted clinically

Pregnancy, seizure disorders, tattoos, and photosensitizing diseases may be relevant in particular patients, but they should not be treated as universal ruby-laser contraindications without considering the treatment site, indication, medication, and device instructions.

The final decision should be based on the patient’s medical assessment, the laser manufacturer’s labeling, and applicable local regulations.

How to Apply This to Practice

Use a standardized consultation and document the following before treatment:

If your primary focus is diagnostic safety: Confirm a benign diagnosis, and biopsy any suspicious or uncertain lesion before laser exposure.
If your primary focus is preventing irreversible dyschromia: Exclude current or previous systemic gold therapy, postpone treatment after tanning or sunburn, and assess baseline skin phototype and pigmentation risk.
If your primary focus is minimizing scarring: Review isotretinoin or retinoid exposure, keloid history, poor wound healing, active inflammation, infection, radiation therapy, and bleeding risk.
If your primary focus is preventing treatment complications: Complete medication and photosensitivity screening, perform a test spot, avoid pulse stacking and excessive overlap, and follow the device’s validated parameters.
If your primary focus is ocular protection: Use certified wavelength-specific eyewear for everyone in the room and maintain protection until the system is safely placed in standby.
If your primary focus is informed consent: Explain possible incomplete clearance, repeat sessions, pigmentary change, scarring, recurrence, and temporary whitening of hair in the treatment zone.

Safe Q-switched ruby laser practice begins with diagnosis and risk stratification, not with selecting a fluence.

Summary Table:

Screening Area	Key Considerations
Lesion Assessment	Biopsy suspicious lesions; confirm benign diagnosis before laser treatment.
Medication History	Exclude systemic gold therapy; review retinoids, photosensitizing drugs.
Skin & Sun Exposure	Postpone after tanning; caution in darker skin types.
Healing & Scarring	Check keloid history, active infections, and wound healing issues.
Ocular Safety	Use certified protective eyewear; ensure safety protocols.
Test Spot	Perform test spot to assess response and refine parameters.

Ensure patient safety with advanced Q-switched ruby laser systems from BELIS. Our professional-grade devices are trusted by clinics and premium salons worldwide. Contact us today for expert guidance and tailored solutions — Request a consultation and elevate your practice with reliable technology and comprehensive support.

Menu

What critical medical contraindications and pre-treatment screening steps should clinical practitioners consider before operating Q-switched ruby laser systems for pigmented lesion removal?